$31.38
+4.8%Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.
Chief Financial Officer
Chief Medical Officer
Compensation
$486,288
Chief Operating Officer
Compensation
$661,829
Chief People Officer
Compensation
$536,487
Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board
Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board
Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board
Co-Founder, Chief Executive Officer, President & Director
Compensation
$919,071
Senior Director of Corporate Development & Portfolio Strategy
Vice President of Technology
During the last 12 months, insiders have purchased $557K and sold $654K worth of SEPN shares, resulting in $97K of net selling activity.
0
0.00
14.4K
415.78K
-416K
-$416K
0
0.00
6.3K
175.11K
-175K
-$175K
33.2K
556.87K
3.5K
63.22K
+494K
+$494K
0
0.00
0
0.00
+0
+$0
Gottesdiener Keith Michael
Director
$557K
Shaikhly Samira
Officer: Chief People Officer
$467K
Bhatt Elizabeth
Officer: President And Coo
$124K
Long Daniel D.
Officer: Svp, Drug Discovery
$63K
Slightly bearish with $97K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
3 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Balanced insider activity: Roughly equal buying and selling suggests normal portfolio management rather than strong directional signals. Look to other metrics for clearer investment insights.
SEPN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 17, 2025 | 2025 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.